U.S., Jan. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07316842) titled 'SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF' on Dec. 01, 2025.
Brief Summary: This study will follow a group of people with chronic hepatitis C infection of genotype 3 who have mild to moderate liver fibrosis (stages F0-F2, measured by a liver stiffness test). All participants will be receiving the antiviral drugs ravidasvir and sofosbuvir as part of their regular medical care.
Only patients who start this treatment, meet the study's eligibility criteria, and give written consent for their medical data to be used in research will take part. They will be monitored during their routine clinic visits while receiving the two-...